Search

Your search keyword '"Bassi, I."' showing total 209 results
Start Over Author "Bassi, I."
209 results on '"Bassi, I."'

5. Myocardial Fibrosis at Cardiac MRI Helps Predict Adverse Clinical Outcome in Patients with Mitral Valve Prolapse

Author

Figliozzi, S. Georgiopoulos, G. Lopes, P.M. Bauer, K.B. Moura-Ferreira, S. Tondi, L. Mushtaq, S. Censi, S. Pavon, A.G. Bassi, I. Servato, M.L. Teske, A.J. Biondi, F. Filomena, D. Pica, S. Torlasco, C. Muraru, D. Monney, P. Quattrocchi, G. Maestrini, V. Agati, L. Monti, L. Pedrotti, P. Vandenberk, B. Squeri, A. Lombardi, M. Ferreira, A.M. Schwitter, J. Aquaro, G.D. Chiribiri, A. Rodríguez Palomares, J.F. Yilmaz, A. Andreini, D. Florian, A. Leiner, T. Abecasis, J. Badano, L.P. Bogaert, J. Masci, P.-G. and Figliozzi, S. Georgiopoulos, G. Lopes, P.M. Bauer, K.B. Moura-Ferreira, S. Tondi, L. Mushtaq, S. Censi, S. Pavon, A.G. Bassi, I. Servato, M.L. Teske, A.J. Biondi, F. Filomena, D. Pica, S. Torlasco, C. Muraru, D. Monney, P. Quattrocchi, G. Maestrini, V. Agati, L. Monti, L. Pedrotti, P. Vandenberk, B. Squeri, A. Lombardi, M. Ferreira, A.M. Schwitter, J. Aquaro, G.D. Chiribiri, A. Rodríguez Palomares, J.F. Yilmaz, A. Andreini, D. Florian, A. Leiner, T. Abecasis, J. Badano, L.P. Bogaert, J. Masci, P.-G.

Abstract

Background: Patients with mitral valve prolapse (MVP) may develop adverse outcomes even in the absence of mitral regurgitation or left ventricular (LV) dysfunction. Purpose: To investigate the prognostic value of mitral annulus disjunction (MAD) and myocardial fibrosis at late gadolinium enhancement (LGE) cardiac MRI in patients with MVP without moderate-to-severe mitral regurgitation or LV dysfunction. Materials and Methods: In this longitudinal retrospective study, 118 144 cardiac MRI studies were evaluated between October 2007 and June 2020 at 15 European tertiary medical centers. Follow-up was from the date of cardiac MRI examination to June 2020; the minimum and maximum follow-up intervals were 6 months and 156 months, respectively. Patients were excluded if at least one of the following conditions was present: cardiomyopathy, LV ejection fraction less than 40%, ischemic heart disease, congenital heart disease, inflammatory heart disease, moderate or worse mitral regurgitation, participation in competitive sport, or electrocardiogram suggestive of channelopathies. In the remainder, cardiac MRI studies were reanalyzed, and patients were included if they were aged 18 years or older, MVP was diagnosed at cardiac MRI, and clinical information and electrocardiogram monitoring were available within 3 months from cardiac MRI examination. The end point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac death (SCD), or unexplained syncope. Multivariable Cox regression analysis was performed. Results: A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 women) were included. Over a median follow-up of 3.3 years, 18 patients (4%) reached the study end point. LGE presence (hazard ratio, 4.2 [95% CI: 1.5, 11.9]; P = .006) and extent (hazard ratio, 1.2 per 1% increase [95% CI: 1.1, 1.4]; P = .006), but not MAD presence (P = .89), were associated with clinical outcome. LGE presence had incremental prognostic value over MVP severi

Published
2023

6. Myocardial Fibrosis at Cardiac MRI Helps Predict Adverse Clinical Outcome in Patients with Mitral Valve Prolapse

Author

Figliozzi, S, Georgiopoulos, G, Lopes, P, Bauer, K, Moura-Ferreira, S, Tondi, L, Mushtaq, S, Censi, S, Pavon, A, Bassi, I, Servato, M, Teske, A, Biondi, F, Filomena, D, Pica, S, Torlasco, C, Muraru, D, Monney, P, Quattrocchi, G, Maestrini, V, Agati, L, Monti, L, Pedrotti, P, Vandenberk, B, Squeri, A, Lombardi, M, Ferreira, A, Schwitter, J, Aquaro, G, Chiribiri, A, Rodríguez Palomares, J, Yilmaz, A, Andreini, D, Florian, A, Leiner, T, Abecasis, J, Badano, L, Bogaert, J, Masci, P, Figliozzi, Stefano, Georgiopoulos, Georgios, Lopes, Pedro M, Bauer, Klemens B, Moura-Ferreira, Sara, Tondi, Lara, Mushtaq, Saima, Censi, Stefano, Pavon, Anna Giulia, Bassi, Ilaria, Servato, Maria Luz, Teske, Arco J, Biondi, Federico, Filomena, Domenico, Pica, Silvia, Torlasco, Camilla, Muraru, Denisa, Monney, Pierre, Quattrocchi, Giuseppina, Maestrini, Viviana, Agati, Luciano, Monti, Lorenzo, Pedrotti, Patrizia, Vandenberk, Bert, Squeri, Angelo, Lombardi, Massimo, Ferreira, António M, Schwitter, Juerg, Aquaro, Giovanni Donato, Chiribiri, Amedeo, Rodríguez Palomares, José F, Yilmaz, Ali, Andreini, Daniele, Florian, Anca, Leiner, Tim, Abecasis, João, Badano, Luigi, Bogaert, Jan, Masci, Pier-Giorgio, Figliozzi, S, Georgiopoulos, G, Lopes, P, Bauer, K, Moura-Ferreira, S, Tondi, L, Mushtaq, S, Censi, S, Pavon, A, Bassi, I, Servato, M, Teske, A, Biondi, F, Filomena, D, Pica, S, Torlasco, C, Muraru, D, Monney, P, Quattrocchi, G, Maestrini, V, Agati, L, Monti, L, Pedrotti, P, Vandenberk, B, Squeri, A, Lombardi, M, Ferreira, A, Schwitter, J, Aquaro, G, Chiribiri, A, Rodríguez Palomares, J, Yilmaz, A, Andreini, D, Florian, A, Leiner, T, Abecasis, J, Badano, L, Bogaert, J, Masci, P, Figliozzi, Stefano, Georgiopoulos, Georgios, Lopes, Pedro M, Bauer, Klemens B, Moura-Ferreira, Sara, Tondi, Lara, Mushtaq, Saima, Censi, Stefano, Pavon, Anna Giulia, Bassi, Ilaria, Servato, Maria Luz, Teske, Arco J, Biondi, Federico, Filomena, Domenico, Pica, Silvia, Torlasco, Camilla, Muraru, Denisa, Monney, Pierre, Quattrocchi, Giuseppina, Maestrini, Viviana, Agati, Luciano, Monti, Lorenzo, Pedrotti, Patrizia, Vandenberk, Bert, Squeri, Angelo, Lombardi, Massimo, Ferreira, António M, Schwitter, Juerg, Aquaro, Giovanni Donato, Chiribiri, Amedeo, Rodríguez Palomares, José F, Yilmaz, Ali, Andreini, Daniele, Florian, Anca, Leiner, Tim, Abecasis, João, Badano, Luigi, Bogaert, Jan, and Masci, Pier-Giorgio

Abstract

Background: Patients with mitral valve prolapse (MVP) may develop adverse outcomes even in the absence of mitral regurgitation or left ventricular (LV) dysfunction. Purpose: To investigate the prognostic value of mitral annulus disjunction (MAD) and myocardial fibrosis at late gadolinium enhancement (LGE) cardiac MRI in patients with MVP without moderate-to-severe mitral regurgitation or LV dysfunction. Materials and Methods: In this longitudinal retrospective study, 118 144 cardiac MRI studies were evaluated between October 2007 and June 2020 at 15 European tertiary medical centers. Follow-up was from the date of cardiac MRI examination to June 2020; the minimum and maximum follow-up intervals were 6 months and 156 months, respectively. Patients were excluded if at least one of the following conditions was present: cardiomyopathy, LV ejection fraction less than 40%, ischemic heart disease, congenital heart disease, inflammatory heart disease, moderate or worse mitral regurgitation, participation in competitive sport, or electrocardiogram suggestive of channelopathies. In the remainder, cardiac MRI studies were reanalyzed, and patients were included if they were aged 18 years or older, MVP was diagnosed at cardiac MRI, and clinical information and electrocardiogram monitoring were available within 3 months from cardiac MRI examination. The end point was a composite of adverse outcomes: sustained ventricular tachycardia (VT), sudden cardiac death (SCD), or unexplained syncope. Multivariable Cox regression analysis was performed. Results: A total of 474 patients (mean age, 47 years ± 16 [SD]; 244 women) were included. Over a median follow-up of 3.3 years, 18 patients (4%) reached the study end point. LGE presence (hazard ratio, 4.2 [95% CI: 1.5, 11.9]; P = .006) and extent (hazard ratio, 1.2 per 1% increase [95% CI: 1.1, 1.4]; P = .006), but not MAD presence (P = .89), were associated with clinical outcome. LGE presence had incremental prognostic value over MVP severi

Published
2023

11. Endothelial Dysfunction in Patients with Advanced Heart Failure Treated with Levosimendan Periodic Infusion Compared with Optimal Medical Therapy: A Pilot Study

Author

Maloberti, A, Sun, J, Zannoni, J, Occhi, L, Bassi, I, Fabbri, S, Colombo, V, Gualini, E, Algeri, M, Varrenti, M, Masciocco, G, Perna, E, Oliva, F, Cipriani, M, Frigerio, M, Giannattasio, C, Maloberti, Alessandro, Sun, Jinwei, Zannoni, Jessica, Occhi, Lucia, Bassi, Ilaria, Fabbri, Saverio, Colombo, Valentina, Gualini, Elena, Algeri, Michela, Varrenti, Marisa, Masciocco, Gabriella, Perna, Enrico, Oliva, Fabrizio, Cipriani, Manlio, Frigerio, Maria, Giannattasio, Cristina, Maloberti, A, Sun, J, Zannoni, J, Occhi, L, Bassi, I, Fabbri, S, Colombo, V, Gualini, E, Algeri, M, Varrenti, M, Masciocco, G, Perna, E, Oliva, F, Cipriani, M, Frigerio, M, Giannattasio, C, Maloberti, Alessandro, Sun, Jinwei, Zannoni, Jessica, Occhi, Lucia, Bassi, Ilaria, Fabbri, Saverio, Colombo, Valentina, Gualini, Elena, Algeri, Michela, Varrenti, Marisa, Masciocco, Gabriella, Perna, Enrico, Oliva, Fabrizio, Cipriani, Manlio, Frigerio, Maria, and Giannattasio, Cristina

Abstract

Endothelial dysfunction (ED) is frequently found in patients with heart failure (HF). Among several pharmacological agents reported to improve endothelial function, levosimendan seems to be a promising one, even though, to date, only two previously published studies have evaluated its effects on ED in these patients. The aim of our pilot study was to further investigate the role of periodic levosimendan infusion on endothelial function in patients affected by advanced HF. In this cross-sectional study, three different groups were enrolled: 20 patients with advanced HF treated with periodic levosimendan (LEVO), 20 patients with HF on optimal medical therapy (OMT), and 20 healthy subjects (control group). ED was evaluated through flow-mediated dilation (FMD) at the level of the brachial artery. The three groups presented similar ages with significant differences in gender distribution, systolic blood pressure, and chronic kidney disease (eGFR < 30 mL/min). In HF patients, ischaemic aetiology was more prevalent in the LEVO group than in the OMT group (60 vs. 40%, p < 0.001). The New York Heart Association (NYHA) functional class was worse in the LEVO group, as well as in NT-proBNP (5636.7 ± 6164.6 ng/dL and 1243.7 ± 1487.2 ng/dL, in the LEVO and OMT groups, respectively, p = 0.005). The FMD was significantly higher in the healthy control group compared to that of the OMT group (15.7 ± 6.4 vs. 9.1 ± 6.0%, p = 0.007) while it showed an intermediate value in LEVO patients (12.4 ± 7.1%) (ANOVA p = 0.010). In conclusion, levosimendan therapy seems to ameliorate endothelial dysfunction related to heart failure. Longitudinal studies in patients on periodic therapy are needed in order to confirm the long-term effects of levosimendan on ED.

Published
2022

12. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial

Author

Salvarani, C, Massari, M, Costantini, M, Franco Merlo, D, Lucia Mariani, G, Viale, P, Nava, S, Guaraldi, G, Dolci, G, Boni, L, Savoldi, L, Bruzzi, P, Turrà, C, Catanoso, M, Maria Marata, A, Barbieri, C, Valcavi, A, Franzoni, F, Cavuto, S, Mazzi, G, Corsini, R, Trapani, F, Bartoloni, A, Barisione, E, Jole Burastero, G, Pan, A, Inojosa, W, Scala, R, Burattini, C, Luppi, F, Codeluppi, M, Eldin Tarek, K, Cenderello, G, Salio, M, Foti, G, Dongilli, R, Bajocchi, G, Alberto Negri, E, Ciusa, G, Fornaro, G, Bassi, I, Zammarchi, L, Aloè, T, Facciolongo, N, Salvarani, Carlo, Massari, Marco, Costantini, Massimo, Franco Merlo, Domenico, Lucia Mariani, Gabriella, Viale, Pierluigi, Nava, Stefano, Guaraldi, Giovanni, Dolci, Giovanni, Boni, Luca, Savoldi, Luisa, Bruzzi, Paolo, Turrà, Caterina, Catanoso, Mariagrazia, Maria Marata, Anna, Barbieri, Chiara, Valcavi, Annamaria, Franzoni, Francesca, Cavuto, Silvio, Mazzi, Giorgio, Corsini, Romina, Trapani, Fabio, Bartoloni, Alessandro, Barisione, Emanuela, Jole Burastero, Giulia, Pan, Angelo, Inojosa, Walter, Scala, Raffaele, Burattini, Cecilia, Luppi, Fabrizio, Codeluppi, Mauro, Eldin Tarek, Kamal, Cenderello, Giovanni, Salio, Mario, Foti, Giuseppe, Dongilli, Roberto, Bajocchi, Gianluigi, Alberto Negri, Emanuele, Ciusa, Giacomo, Fornaro, Giacomo, Bassi, Ilaria, Zammarchi, Lorenzo, Aloè, Teresita, Facciolongo, Nicola, Salvarani, C, Massari, M, Costantini, M, Franco Merlo, D, Lucia Mariani, G, Viale, P, Nava, S, Guaraldi, G, Dolci, G, Boni, L, Savoldi, L, Bruzzi, P, Turrà, C, Catanoso, M, Maria Marata, A, Barbieri, C, Valcavi, A, Franzoni, F, Cavuto, S, Mazzi, G, Corsini, R, Trapani, F, Bartoloni, A, Barisione, E, Jole Burastero, G, Pan, A, Inojosa, W, Scala, R, Burattini, C, Luppi, F, Codeluppi, M, Eldin Tarek, K, Cenderello, G, Salio, M, Foti, G, Dongilli, R, Bajocchi, G, Alberto Negri, E, Ciusa, G, Fornaro, G, Bassi, I, Zammarchi, L, Aloè, T, Facciolongo, N, Salvarani, Carlo, Massari, Marco, Costantini, Massimo, Franco Merlo, Domenico, Lucia Mariani, Gabriella, Viale, Pierluigi, Nava, Stefano, Guaraldi, Giovanni, Dolci, Giovanni, Boni, Luca, Savoldi, Luisa, Bruzzi, Paolo, Turrà, Caterina, Catanoso, Mariagrazia, Maria Marata, Anna, Barbieri, Chiara, Valcavi, Annamaria, Franzoni, Francesca, Cavuto, Silvio, Mazzi, Giorgio, Corsini, Romina, Trapani, Fabio, Bartoloni, Alessandro, Barisione, Emanuela, Jole Burastero, Giulia, Pan, Angelo, Inojosa, Walter, Scala, Raffaele, Burattini, Cecilia, Luppi, Fabrizio, Codeluppi, Mauro, Eldin Tarek, Kamal, Cenderello, Giovanni, Salio, Mario, Foti, Giuseppe, Dongilli, Roberto, Bajocchi, Gianluigi, Alberto Negri, Emanuele, Ciusa, Giacomo, Fornaro, Giacomo, Bassi, Ilaria, Zammarchi, Lorenzo, Aloè, Teresita, and Facciolongo, Nicola

Abstract

Rationale Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus disease 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia. Methods In this multicentre, randomised, double-blind, placebo-controlled trial, 304 hospitalised patients with COVID-19 pneumonia were randomised to receive 1 g of methylprednisolone intravenously for three consecutive days or placebo in addition to standard dexamethasone. The primary outcome was the duration of patient hospitalisation, calculated as the time interval between randomisation and hospital discharge without the need for supplementary oxygen. The key secondary outcomes were survival free from invasive ventilation with orotracheal intubation and overall survival. Results Overall, 112 (75.4%) out of 151 patients in the pulse methylprednisolone arm and 111 (75.2%) of 150 in the placebo arm were discharged from hospital without oxygen within 30 days from randomisation. Median time to discharge was similar in both groups (15 days, 95% CI 13.0–17.0 days and 16 days, 95% CI 13.8–18.2 days, respectively; hazard ratio (HR) 0.92, 95% CI 0.71–1.20; p=0.528). No significant differences between pulse methylprednisolone and placebo arms were observed in terms of admission to intensive care unit with orotracheal intubation or death (20.0% versus 16.1%; HR 1.26, 95% CI 0.74–2.16; p=0.176) or overall mortality (10.0% versus 12.2%; HR 0.83, 95% CI 0.42–1.64; p=0.584). Serious adverse events occurred with similar frequency in the two groups. Conclusions Methylprenisolone pulse therapy added to dexamethasone was not of benefit in patients with COVID-19 pneumonia.

Published
2022

16. Generation of specialized blood vessels through transdifferentiation of lymphatic endothelial cells

Author

Brückner M, Lambiase G, Bassi I, Wiebke Herzog, Julian Nicenboim, Kenneth D. Poss, Hirsch D, Noga Moshe, Das Rn, Yaara Tevet, Safriel S, Eilam-Altstadter R, Han Y, and Karina Yaniv

Subjects
0303 health sciences, biology, Regeneration (biology), government.form_of_government, Transdifferentiation, Cell Ontogeny, Cell fate determination, biology.organism_classification, Cell biology, 03 medical and health sciences, Lymphatic Endothelium, 0302 clinical medicine, Lymphatic system, government, Progenitor cell, Zebrafish, 030217 neurology & neurosurgery, 030304 developmental biology
Abstract

The lineage and developmental trajectory of a cell are key determinants of cellular identity. Yet, the functional relevance of deriving a specific cell type from ontologically distinct progenitors, remains an open question. In the case of the vascular system, blood and lymphatic vessels are composed of endothelial cells (ECs) that differentiate and diversify to cater the different physiological demands of each organ. While lymphatic vessels have been shown to originate from multiple cell sources, lymphatic ECs (LECs) themselves seem to have a unipotent cell fate. In this work we uncover a novel mechanism of blood vessel formation through transdifferentiation of LECs. Using advanced long-term reiterative imaging and lineage-tracing of ECs in zebrafish, from embryonic development through adulthood, we reveal a hitherto unknown process of LEC-to-BEC transdifferentiation, underlying vascularization of the anal fin (AF). Moreover, we demonstrate distinct functional implications for deriving AF vessels from either LECs or BECs, uncovering for the first time a clear link between cell ontogeny and functionality. Molecularly, we identify Sox17 as a negative regulator of lymphatic fate specification, whose specific expression in AF LECs suppresses its lymphatic cell fate. Finally, we show that akin to the developmental process, during adult AF regeneration the vasculature is re-derived from lymphatics, demonstrating that LECs in the mature fish retain both potency and plasticity for generating specialized blood vessels. Overall, our work highlights a novel mechanism of blood vessel formation through LEC trans-differentiation, and provides the first in vivo evidence for a link between cell ontogeny and functionality in ECs.

Published
2021
Full Text
View/download PDF

17. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment

Author

Cerri, S, Monari, M, Guerrieri, A, Donatelli, P, Bassi, I, Garuti, M, Luppi, F, Betti, S, Bandelli, G, Carpano, M, Bacchi Reggiani, M, Tonelli, R, Clini, E, Nava, S, Cerri S., Monari M., Guerrieri A., Donatelli P., Bassi I., Garuti M., Luppi F., Betti S., Bandelli G., Carpano M., Bacchi Reggiani M. L., Tonelli R., Clini E., Nava S., Cerri, S, Monari, M, Guerrieri, A, Donatelli, P, Bassi, I, Garuti, M, Luppi, F, Betti, S, Bandelli, G, Carpano, M, Bacchi Reggiani, M, Tonelli, R, Clini, E, Nava, S, Cerri S., Monari M., Guerrieri A., Donatelli P., Bassi I., Garuti M., Luppi F., Betti S., Bandelli G., Carpano M., Bacchi Reggiani M. L., Tonelli R., Clini E., and Nava S.

Abstract

Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathic pulmonary fibrosis (IPF) are still scarce. Methods: We compared the efficacy of either pirfenidone (n = 78) or nintedanib (n = 28) delivered over a 24-month period in patients with IPF, followed at two regional clinic centers in Italy, with a group of patients who refused the treatment (n = 36), and who were considered to be controls. All patients completed regular visits at 1- to 3-month intervals, where primary [forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)] and secondary outcomes (side effects, treatment compliance, and mortality) were recorded. Results: Over time, the decline in FVC and DLCO was significantly higher (p = 0.0053 and p = 0.037, respectively) in controls when compared with the combined treated group, with no significant difference between the two treated groups. Compared to patients with less advanced disease (GAP (Gender, Age, Physiology) stage I), those in GAP stages II and III showed a significantly higher decline in both FVC and DLCO irrespective of the drug taken. Side effects were similarly reported in patients receiving pirfenidone and nintedanib (5% and 7%, respectively), whereas mortality did not differ among the three groups. Conclusion: This real-life study demonstrated that both pirfenidone and nintedanib were equally effective in reducing the decline of FVC and DLCO versus non-treated patients after 24 months of treatment; however, patients with more advanced disease were likely to show a more rapid decline in respiratory function

Published
2019

18. Getting to the heart of the matter in a multisystem disorder: Erdheim–Chester disease

Author

Buono, A, Bassi, I, Santolamazza, C, Moreo, A, Pedrotti, P, Sacco, A, Morici, N, Giannattasio, C, Oliva, F, Ammirati, E, Buono A., Bassi I., Santolamazza C., Moreo A., Pedrotti P., Sacco A., Morici N., Giannattasio C., Oliva F., Ammirati E., Buono, A, Bassi, I, Santolamazza, C, Moreo, A, Pedrotti, P, Sacco, A, Morici, N, Giannattasio, C, Oliva, F, Ammirati, E, Buono A., Bassi I., Santolamazza C., Moreo A., Pedrotti P., Sacco A., Morici N., Giannattasio C., Oliva F., and Ammirati E.

Published
2019

20. URIC ACID IN ACUTE CORONARY SYNDROME: CORRELATIONS WITH IN-HOSPITAL MORTALITY AND COMPLICATIONS

Author

Maloberti, A, Rebora, P, Morici, N, Sacco, A, Viola, G, Lattuada, F, Molinari, V, Occhi, L, Bassi, I, Portoghese, A, Fortina, M, Oliva, F, Giannattasio, C, Maloberti, Alessandro, Rebora, Paola, Morici, Nuccia, Sacco, Alica, Viola, Giovanna, Lattuada, Francesca, Molinari, Valentina, Occhi, Lucia, Bassi, Ilaria, Portoghese, Alessandro, Fortina, Matteo, Oliva, Fabrizio, Giannattasio, Cristina, Maloberti, A, Rebora, P, Morici, N, Sacco, A, Viola, G, Lattuada, F, Molinari, V, Occhi, L, Bassi, I, Portoghese, A, Fortina, M, Oliva, F, Giannattasio, C, Maloberti, Alessandro, Rebora, Paola, Morici, Nuccia, Sacco, Alica, Viola, Giovanna, Lattuada, Francesca, Molinari, Valentina, Occhi, Lucia, Bassi, Ilaria, Portoghese, Alessandro, Fortina, Matteo, Oliva, Fabrizio, and Giannattasio, Cristina

Published
2021

21. Low Awareness of Cardiovascular Risk Factor Among Patients Admitted in Cardiac Rehabilitation: New Data for Further Implementation of Cardiovascular Rehabilitation Program

Author

Maloberti, A, Monticelli, M, Bassi, I, Riccobono, S, Giannattasio, C, Maloberti, Alessandro, Monticelli, Massimiliano, Bassi, Ilaria, Riccobono, Salvatore, Giannattasio, Cristina, Maloberti, A, Monticelli, M, Bassi, I, Riccobono, S, Giannattasio, C, Maloberti, Alessandro, Monticelli, Massimiliano, Bassi, Ilaria, Riccobono, Salvatore, and Giannattasio, Cristina

Published
2021

24. Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH)

Author

Bonomi, M., Vezzoli, V., Krausz, C., Guizzardi, F., Vezzani, S., Simoni, M., Bassi, I., Duminuco, P., Di Iorgi, N., Giavoli, C., Pizzocaro, A., Russo, G., Moro, M., Fatti, L., Ferlin, A., Mazzanti, L., Zatelli, M. C., Cannavo, S., Isidori, A. M., Pincelli, A. I., Prodam, F., Mancini, A., Limone, P., Tanda, M. L., Gaudino, R., Salerno, M., Francesca, P., Maghnie, M., Maggi, M. C., Persani, L., Aimaretti, G., Altobell, M., Ambrosio, M. R., Andrioli, M., Angelett, G., Arecco, F., Arnald, G., Arosio, M., Balsamo, A., Baldassarr, M., Bartalena, L., Bazzon, N., Beccari, L., Beck-Peccoz, P., Bellastella, G., Bellizz, M., Benedicent, F., Bernasconi, S., Bizzarri, C., Bona, G., Bonadonna, S., Borrett, G., Boschetti, M., Brunani, A., Brunelli, V., Buz, F., Cacciatore, C., Cangiano, B., Cappa, M., Casalone, R., Cassio, A., Cavarzere, P., Cherubini, V., Ciampani, T., Cicognan, D., Cignarell, A., Cisternin, M., Colombo, P., Corbetta, S., Corciul, N., Corona, G., Cozzi, R., Crivellaro, C., Dalle Mule, I., Danesi, L., Eli, A. V. D., Degli Uberti, E., De Leo, S., Della Valle, E., De Marchi, M., Di Mambr, A., Fabbri, A., Foresta, C., Forti, G., Franceschi, A. R., Garolla, A., Ghezzi, M., Giacomozzi, C., Giusti, M., Grosso, E., Guabello, G., Guarneri, M. P., Grugni, G., Lanfranco, F., Lania, A., Lanzi, R., Larizza, L., Lenzi, A., Loche, S., Loli, P., Lombardi, V., Mandrile, G., Manieri, C., Mantovani, G., Marelli, S., Marzullo, M., Mencarelli, M. A., Migone, N., Motta, G., Neri, G., Padov, G., Parenti, G., Pasquino, B., Pia, A., Piantanida, E., Pignatti, E., Pilotta, A., Pivett, B., Pollazzon, M., Pontecorvi, A., Porcelli, P., Pozza, G. B., Pozzobon, G., Radetti, G., Razzore, P., Rocchett, L., Roncoron, R., Rossi, G., Sala, E., Salvatoni, A., Salvini, F., Secc, A., Segni, M., Selice, R., Sgaramella, P., Sileo, F., Sinisi, A. A., Sirchia, F., Spada, A., Tresoldi, A., Vigneri, R., Weber, G., Zucchini, S., Bassi I., Moro M., Pincelli A. I., Mancini A. (ORCID:0000-0002-7707-4564), Cappa M., Corbetta S., Corona G., Danesi L., Ghezzi M., Giusti M. (ORCID:0000-0001-5767-8785), Grugni G., Parenti G., Pontecorvi A. (ORCID:0000-0003-0570-6865), Sala E., Bonomi, M., Vezzoli, V., Krausz, C., Guizzardi, F., Vezzani, S., Simoni, M., Bassi, I., Duminuco, P., Di Iorgi, N., Giavoli, C., Pizzocaro, A., Russo, G., Moro, M., Fatti, L., Ferlin, A., Mazzanti, L., Zatelli, M. C., Cannavo, S., Isidori, A. M., Pincelli, A. I., Prodam, F., Mancini, A., Limone, P., Tanda, M. L., Gaudino, R., Salerno, M., Francesca, P., Maghnie, M., Maggi, M. C., Persani, L., Aimaretti, G., Altobell, M., Ambrosio, M. R., Andrioli, M., Angelett, G., Arecco, F., Arnald, G., Arosio, M., Balsamo, A., Baldassarr, M., Bartalena, L., Bazzon, N., Beccari, L., Beck-Peccoz, P., Bellastella, G., Bellizz, M., Benedicent, F., Bernasconi, S., Bizzarri, C., Bona, G., Bonadonna, S., Borrett, G., Boschetti, M., Brunani, A., Brunelli, V., Buz, F., Cacciatore, C., Cangiano, B., Cappa, M., Casalone, R., Cassio, A., Cavarzere, P., Cherubini, V., Ciampani, T., Cicognan, D., Cignarell, A., Cisternin, M., Colombo, P., Corbetta, S., Corciul, N., Corona, G., Cozzi, R., Crivellaro, C., Dalle Mule, I., Danesi, L., Eli, A. V. D., Degli Uberti, E., De Leo, S., Della Valle, E., De Marchi, M., Di Mambr, A., Fabbri, A., Foresta, C., Forti, G., Franceschi, A. R., Garolla, A., Ghezzi, M., Giacomozzi, C., Giusti, M., Grosso, E., Guabello, G., Guarneri, M. P., Grugni, G., Lanfranco, F., Lania, A., Lanzi, R., Larizza, L., Lenzi, A., Loche, S., Loli, P., Lombardi, V., Mandrile, G., Manieri, C., Mantovani, G., Marelli, S., Marzullo, M., Mencarelli, M. A., Migone, N., Motta, G., Neri, G., Padov, G., Parenti, G., Pasquino, B., Pia, A., Piantanida, E., Pignatti, E., Pilotta, A., Pivett, B., Pollazzon, M., Pontecorvi, A., Porcelli, P., Pozza, G. B., Pozzobon, G., Radetti, G., Razzore, P., Rocchett, L., Roncoron, R., Rossi, G., Sala, E., Salvatoni, A., Salvini, F., Secc, A., Segni, M., Selice, R., Sgaramella, P., Sileo, F., Sinisi, A. A., Sirchia, F., Spada, A., Tresoldi, A., Vigneri, R., Weber, G., Zucchini, S., Bassi I., Moro M., Pincelli A. I., Mancini A. (ORCID:0000-0002-7707-4564), Cappa M., Corbetta S., Corona G., Danesi L., Ghezzi M., Giusti M. (ORCID:0000-0001-5767-8785), Grugni G., Parenti G., Pontecorvi A. (ORCID:0000-0003-0570-6865), and Sala E.

Abstract

Objective: Isolated hypogonadotropic hypogonadism (IHH) is a rare disorder with pubertal delay, normal (normoosmic-IHH, nIHH) or defective sense of smell (Kallmann syndrome, KS). Other reproductive and nonreproductive anomalies might be present although information on their frequency are scanty, particularly according to the age of presentation. Design: Observational cohort study carried out between January 2008 and June 2016 within a national network of academic or general hospitals. Methods: We performed a detailed phenotyping of 503 IHH patients with: (1) manifestations of hypogonadism with low sex steroid hormone and low/normal gonadotropins; (2) absence of expansive hypothalamic/pituitary lesions or multiple pituitary hormone defects. Cohort was divided on IHH onset (PPO, pre-pubertal onset or AO, adult onset) and olfactory function: PPO-nIHH (n = 275), KS (n = 184), AO-nIHH (n = 36) and AO-doIHH (AO-IHH with defective olfaction, n = 8). Results: 90% of patients were classifed as PPO and 10% as AO. Typical midline and olfactory defects, bimanual synkinesis and familiarity for pubertal delay were also found among the AO-IHH. Mean age at diagnosis was signifcantly earlier and more frequently associated with congenital hypogonadism stigmata in patients with Kallmann's syndrome (KS). Synkinesis, renal and male genital tract anomalies were enriched in KS. Overweight/obesity are signifcantly associated with AO-IHH rather than PPO-IHH. Conclusions: Patients with KS are more prone to develop a severe and complex phenotype than nIHH. The presence of typical extra-gonadal defects and familiarity for PPO-IHH among the AO-IHH patients indicates a common predisposition with variable clinical expression. Overall, these fndings improve the understanding of IHH and may have a positive impact on the management of patients and their families.

Published
2018

27. Psychological determinants of target organ damage in hypertensive patients: focus on Pulse Wave Velocity and depression

Author

Greco, A, Maloberti, A, Varrenti, M, Bassi, I, PICCINELLI, ENRICO, Panzera, F, Laurent, S, Boutouyrie, P, D’Addario, M, Annoni, AM, Steca, P, Giannattasio, C, Greco, A, Maloberti, A, Varrenti, M, Bassi, I, Piccinelli, E, Panzera, F, Laurent, S, Boutouyrie, P, D’Addario, M, Annoni, A, Steca, P, and Giannattasio, C

Subjects
hypertensive patient, organ damage, pulse wave velocity, Hypertension, depression
Published
2017

28. Effects of chronic heart failure unconventional therapies on endothelial function

Author

Piccinelli, E, Maloberti, A, Zannoni, J, Castelnuovo, S, Vallerio, P, Bassi, I, Pansera, G, Occhi, L, Varrenti, M, Masciocco, G, Perna, E, Cipriani, M, Frigerio, M, Giannattasio, C, Piccinelli, E, Maloberti, A, Zannoni, J, Castelnuovo, S, Vallerio, P, Bassi, I, Pansera, G, Occhi, L, Varrenti, M, Masciocco, G, Perna, E, Cipriani, M, Frigerio, M, and Giannattasio, C

Abstract

Introduction: Endothelial dysfunction (ED) of peripheral arteries in chronic heart failure (CHF) subjects has been demonstrated. We assessed endothelial function in subjects undergoing unconventional treatments for CHF, namely heart transplantation (HTX), continuous-flow left ventricular assist device implantation (LVAD), and repeated levosimendan infusions (r-LEVO). Methods: Twenty HTX recipients (median time from HTX 21 months), 20 patients supported with LVAD (median time from implant 39 months), and 20 patients receiving monthly Levosimendan infusions (median time on treatment 28 months) were enrolled and compared to a group of 20 healthy subjects. ED was evaluated with ultrasound assessment of the diameter before and after ischemic stress at the brachial artery level. The difference between the two diameters normalized for the baseline value (flow mediated dilation–FMD) has been used for the analysis. All the patients were stable at the time of FMD assessment, with those on r-LEVO being evaluated prior to infusion. Results: FMD was significantly lower in HTX and LVAD groups with respect to controls (9.8 ± 7.4, 9.3 ± 5.7, and 15.6 ± 6.4% respectively, p = 0.01), but not in r-LEVO group (12.5 ± 6.9%). When patients were analysed according to time from the operation or on treatment, (< versus ≥ of the median value), no differences were seen in HTX and r-LEVO group, while in LVAD group FMD was borderline significantly higher in patients with longer follow-up (8.4 ± 6.4% versus 10.2 ± 5.2%, p = 0.05). Conclusions: Based on this preliminary data we can inference the following: 1- FMD is abnormal in HTX recipients, despite their good functional status, probably due to factors unrelated to CHF (e.g. hypertension, renal insufficiency, denervation, and drug effects); 2- LVAD patients also show ED, with possible better adaptation in very long-term survivors; 3- Near-normal FMD values in CHF patients who remain stable with r-LEVO suggest that pulsed treatment may obtain

Published
2019

29. Vascular Aging and Disease of the Large Vessels: Role of Inflammation

Author

Maloberti, A, Vallerio, P, Triglione, N, Occhi, L, Panzeri, F, Bassi, I, Pansera, F, Piccinelli, E, Peretti, A, Garatti, L, Palazzini, M, Sun, J, Grasso, E, Giannattasio, C, Maloberti, A, Vallerio, P, Triglione, N, Occhi, L, Panzeri, F, Bassi, I, Pansera, F, Piccinelli, E, Peretti, A, Garatti, L, Palazzini, M, Sun, J, Grasso, E, and Giannattasio, C

Abstract

Structural and functional arterial properties commonly impair with aging process. These effects on vasculature could act at many levels from microcirculation to large vessels. Above normal aging process classic cardio-vascular risk factors (hypertension, diabetes mellitus, dyslipidemia, etc.) accelerate the physiological process leading to premature structural and functional alterations that has also been termed early vascular aging. Target organ damage evaluation could be clinically important since these alterations precede by many years' cardiovascular events and so their assessment can predict the onset of more serious and costly events giving the opportunity to prevent CV events by earlier therapeutic intervention. This review will focus on large artery functional properties and particularly on the role of inflammation on the aortic stiffening process.

Published
2019

30. Effects of Chronic Heart Failure Unconventional Therapies on Endothelial Function

Author

Giannattasio, C, Maloberti, A, Piccinelli, E, Zanoni, J, Castelnuovo, S, Vallerio, P, Bassi, I, Pansera, F, Occhi, L, Varrenti, M, Masciocco, G, Perna, E, Cipriani, M, Frigerio, M, C. Giannattasio, A. Maloberti, E. Piccinelli, J. Zanoni, S. Castelnuovo, P. Vallerio, I. Bassi, F. Pansera, L. Occhi, M. Varrenti, G. Masciocco, E. Perna, M. Cipriani, M. Frigerio, Giannattasio, C, Maloberti, A, Piccinelli, E, Zanoni, J, Castelnuovo, S, Vallerio, P, Bassi, I, Pansera, F, Occhi, L, Varrenti, M, Masciocco, G, Perna, E, Cipriani, M, Frigerio, M, C. Giannattasio, A. Maloberti, E. Piccinelli, J. Zanoni, S. Castelnuovo, P. Vallerio, I. Bassi, F. Pansera, L. Occhi, M. Varrenti, G. Masciocco, E. Perna, M. Cipriani, and M. Frigerio

Published
2019

32. A new technique with high reproducibility to estimate renal oxygenation using BOLD-MRI in chronic kidney disease

Author

Piskunowicz M Hofmann L Zuercher E Bassi I Milani B Stuber M Narkiewicz K Vogt B Burnier M

Abstract

Objectives To assess inter observer variability of renal blood oxygenation level dependent MRI (BOLD MRI) using a new method of analysis called the concentric objects (CO) technique in comparison with the classical ROI (region of interest) based technique. Methods MR imaging (3 T) was performed before and after furosemide in 10 chronic kidney disease (CKD) patients (mean eGFR 43 ± 24 ml/min/1.73 m2) and 10 healthy volunteers (eGFR 101 ± 28 ml/min1.73 m2) and R2 maps were determined on four coronal slices. In the CO technique R2 values were based on a semi automatic procedure that divided each kidney in six equal layers whereas in the ROI technique all circles (ROIs) were placed manually in the cortex and medulla. The mean R2values as assessed by two independent investigators were compared. Results With the CO technique inter observer variability was 0.7–1.9 across all layers in non CKD versus 1.6–3.8 in CKD. With the ROI technique median variability for cortical and medullary R2 values was 3.6 and 6.8 in non CKD versus 4.7 and 12.5 in CKD; similar results were observed after furosemide. Conclusion The CO technique offers a new investigator independent highly reproducible alternative to the ROI based technique to estimate renal tissue oxygenation in CKD.

Published
2015

34. EVALUATION OF THE EFFECTS OF MONACOLIN K ON LIPID PROFILE AND ARTERIAL FUNCTION IN DYSLIPIDEMIC PATIENTS

Author

Castelnuovo, S., primary, Bosisio, R., additional, Pavanello, C., additional, Vallerio, P., additional, Maloberti, A., additional, D’Angelo, L., additional, Triglione, N., additional, Montero, B. Lopez, additional, Giupponi, L., additional, Piccinelli, E., additional, Bassi, I., additional, Panzeri, F., additional, Mombelli, G.G., additional, Calabresi, L., additional, and Giannattasio, C., additional

Published
2018
Full Text
View/download PDF

35. In healthy normotensive subjects age and blood pressure better predict subclinical vascular and cardiac organ damage than atherosclerosis biomarkers

Author

Maloberti, A, Farina, F, Carbonaro, M, Piccinelli, E, Bassi, I, Pansera, F, Grassi, G, Mancia, G, Palestini, P, Giannattasio, C, Maloberti, A, Farina, F, Carbonaro, M, Piccinelli, E, Bassi, I, Pansera, F, Grassi, G, Mancia, G, Palestini, P, and Giannattasio, C

Abstract

Purpose: Only few studies evaluated biomarkers useful for defining the cardiovascular risk of a subject in a pre-clinical condition (i.e. healthy subjects). In this context we sought to determine the relationships of Plasminogen activator inhibitor type 1 (PAI‐1), P-Selectin, Tissue Inhibitors Metalloproteinases type 1 (TIMP-1) and Cystatin-C with subclinical Target Organ Damage (TOD) in normotensive and normoglycemic subjects without known cardiovascular and kidney diseases. Materials and Methods: 480 blood donors participated at the present analysis. TOD was evaluated as Pulse Wave Velocity (PWV), Left Ventricular Hypertrophy (LVH) and Intima Media Thickness (IMT) and carotid plaque presence) grouped together under carotid TOD. Results: 3.1% of the subjects showed a PWV higher than 10 m/sec with those subjects exerting significantly lower values of P-Selectine (0.068 ± 0.015 vs 0.08 ± 0.036 mg/L, p =.014). 8.8% of the subjects showed carotid TOD that was associated with higher Cystatin-C values (0.67 ± 0.17 vs 0.63 ± 0.14 mg/L, p =.045). Finally 23.8% of the subjects showed LVH with no significant differences regarding biomarkers. Despite some significant correlations between biomarkers and TOD, at the multivariate analysis none came out to be as significant predictor of the assessed TOD. Conclusions: in normotensive and normoglycemic healthy subjects, the evaluated biomarkers of atherosclerotic process didn’t show any significant association with cardiac, carotid and vascular TOD while age and BP are its principal predictors.

Published
2018

36. Evaluation of the effects of monacolin k on lipid profile and arterial function in dyslipidemic patients.

Author

Castelnuovo, S, Bosisio, R, Pavanello, C, Vallerio, P, Maloberti, A, D’Angelo, L, Triglione, N, Lopez Montero, B, Giupponi, L, Piccinelli, E, Bassi, I, Panzeri, F, Mombelli, G, Calabresi, L, Giannattasio, C, S. Castelnuovo, R. Bosisio, C. Pavanello, P. Vallerio, A. Maloberti, L. D’Angelo, N. Triglione, B. Lopez Montero, L. Giupponi, E. Piccinelli, I. Bassi, F. Panzeri, G. G. Mombelli, L. Calabresi, C. Giannattasio., Castelnuovo, S, Bosisio, R, Pavanello, C, Vallerio, P, Maloberti, A, D’Angelo, L, Triglione, N, Lopez Montero, B, Giupponi, L, Piccinelli, E, Bassi, I, Panzeri, F, Mombelli, G, Calabresi, L, Giannattasio, C, S. Castelnuovo, R. Bosisio, C. Pavanello, P. Vallerio, A. Maloberti, L. D’Angelo, N. Triglione, B. Lopez Montero, L. Giupponi, E. Piccinelli, I. Bassi, F. Panzeri, G. G. Mombelli, L. Calabresi, and C. Giannattasio.

Published
2018

37. Market opportunities for social farms

Author

Bassi, I, Nassivera, F, and Piani, L.

Subjects
multifunctionality, social farms, ethical food, market opportunities, multifunctionality, rural development, social farms, ethical food, market opportunities, rural development
Abstract

Although social farming is seen as a successful and innovative sector, social farms face various challenges, among which the need to find additional income required to stay in business. However, assuming that social farm food is considered as having ethical attributes, the research aims at investigating to what extent consumers are conscious of some ethical concerns (problems related to social hardship, social equity, food quality etc.), and whether this will create market opportunities for social farm food. The study area is the province of Pordenone (Italy). The results indicate that conscious consumers could represent an effective market channel also for social farm food, a notable opportunity for farms to improve their socioeconomic performance., Italian Review of Agricultural Economics, Vol 71 No 2 (2016)

Published
2016
Full Text
View/download PDF

38. Isomorphism in synthetic macromolecular systems

Author

Allegra, G., Bassi, I. W., Cantow, H. -J., editor, Dall'Asta, G., editor, Ferry, J. D., editor, Fujita, H., editor, Kern, W., editor, Natta, G., editor, Okamura, S., editor, Overberger, C. G., editor, Prins, W., editor, Schulz, G. V., editor, Slichter, W. P., editor, Staverman, A. J., editor, Stille, J. K., editor, and Stuart, H. A., editor

Published
1969
Full Text
View/download PDF

39. HYBRID STAGED REVASCULARIZATION OF SEVERE THREE–VESSEL DISEASE ENSURED SAFE MAJOR ONCOLOGIC GASTRIC SURGERY

Author

Biolcati, M, Bassi, I, and Cannata, A

Abstract

A 71–years–old man with multiple cardiovascular risk factors and an old history of paroxysmal AF (non–anticoagulated due to a single episode in youth) was diagnosed with a non–metastatic adenocarcinoma of gastric fundus judged resectable. During infusion of the third cycle of pre–operative CT with FLOT he experienced transitory chest pain with the development of sharpened T waves with a high J point in antero–lateral leads at the EKG during the symptom (fig. 1). The episode was at first considered compatible with vasospasm induced by 5–FU, but a CT scan was nonetheless performed showing a severe three–vessel CAD involving the left main coronary artery (fig. 2), confirmed by the coronary angiography. A normal systolic function was found at the cardiac ultrasound. After the multidisciplinary team including cardiologists, cardiac surgeons, anaesthesiologists, oncologists and gastric surgeons discussed the case, the patient was referred to an urgent off–pump single CABG of the LAD coronary artery with LIMA. That allowed the non–delayable program of total gastrectomy – which was conducted for weeks later – in a safe setting by revascularizing the prognostic vessel and avoiding the DAPT related to a PCI (an eventual bridge therapy with intravenous P2Y12 inhibitors during the first month of stenting of a critical coronary artery was considered at high risk); in addition, the choice of OPCAB prevented the augmented risk of complications of extracorporeal circulation described in oncologic patients such as bleeding and higher mortality (Vieira et al, 2012). Once no residual local or metastatic disease was established, a complete revascularization was performed in election few weeks later by PCI of the residual vessels, which avoided the problems related to a re–sternotomy of a possible second CABG with venous grafts. After six months, the patient was still alive and concluded the remaining two cycles of adjuvant CT safely.

Published
2024
Full Text
View/download PDF

40. A Network Approach to the Analysis of Multifunctional Local Systems

Author

Bassi, I., DE STEFANO, Domenico, Zaccarin, Susanna, ARS'13 Scientific Committee, I., Bassi, DE STEFANO, Domenico, and Zaccarin, Susanna

Subjects
Triadic Analysi, Multifunctional Local System, Social Network Analysis, Triadic Analysis, Collective Action, Rural Development, Social Network Analysi
Published
2013

46. CKD LAB METHODS, PROGRESSION & RISK FACTORS 1

Author

Heisterkamp, M., primary, Titze, S., additional, Lorenzen, J., additional, Eckardt, K.-U., additional, Koettgen, A., additional, Kielstein, J. T., additional, Bouquegneau, A., additional, Vidal-Petiot, E., additional, Vrtovsnik, F., additional, Cavalier, E., additional, Krzesinski, J. M., additional, Flamant, M., additional, Delanaye, P., additional, Anguiano, L., additional, Riera, M., additional, Pascual, J., additional, Barrios, C., additional, Betriu, A., additional, Valdivielso, J. M., additional, Fernandez, E., additional, Soler, M. J., additional, Denys, M.-A., additional, Viaene, A., additional, Goessaert, A.-S., additional, Delanghe, J., additional, Everaert, K., additional, Kim, Y. S., additional, Choi, M. J., additional, Deok, J. Y., additional, Kim, S. G., additional, Bevc, S., additional, Hojs, N., additional, Hojs, R., additional, Ekart, R., additional, Gorenjak, M., additional, Puklavec, L., additional, Piskunowicz, M., additional, Hofmann, L., additional, Zurcher, E., additional, Bassi, I., additional, Zweiacker, C., additional, Stuber, M., additional, Narkiewicz, K., additional, Vogt, B., additional, Burnier, M., additional, Pruijm, M., additional, Rusu, E., additional, Zilisteanu, D., additional, Atasie, T., additional, Circiumaru, A., additional, Carstea, F., additional, Ecobici, M., additional, Rosca, M., additional, Tanase, C., additional, Mihai, S., additional, Voiculescu, M., additional, Jeon, Y. D., additional, Polenakovic, M., additional, Pop-Jordanova, N., additional, Hung, S.-C., additional, Tarng, D.-C., additional, Tuta, L., additional, Stanigut, A., additional, Mesiano, P., additional, Rollino, C., additional, Ferro, M., additional, Beltrame, G., additional, Massara, C., additional, Quattrocchio, G., additional, Borca, M., additional, Bazzan, M., additional, Roccatello, D., additional, Maksudova, A., additional, Urasaeva, L. I., additional, Khalfina, T. N., additional, Tekce, H., additional, Kin Tekce, B., additional, Aktas, G., additional, Alcelik, A., additional, Sengul, E., additional, Lindic, J., additional, Purg, D., additional, Skamen, J., additional, Krsnik, M., additional, Skoberne, A., additional, Pajek, J., additional, Kveder, R., additional, Bren, A., additional, Kovac, D., additional, Delgado, G., additional, Drechsler, C., additional, Wanner, C., additional, Blouin, K., additional, Pilz, S., additional, Tomaschitz, A., additional, Kleber, M. E., additional, Willmes, C., additional, Krane, V., additional, Marz, W., additional, Ritz, E., additional, Van Gilst, W. H., additional, Van Der Harst, P., additional, De Boer, R. A., additional, Scholze, A., additional, Petersen, L., additional, Hocher, B., additional, Rasmussen, L. M., additional, Tepel, M., additional, De Paula, E. A., additional, Vanelli, C. P., additional, Caminhas, M. S., additional, Soares, B. C., additional, Bassoli, F. A., additional, Da Costa, D. M. N., additional, Lanna, C. M. M., additional, Galil, A. G. S., additional, Colugnati, F. A. B., additional, Costa, M. B., additional, Bastos, M. G., additional, De Paula, R. B., additional, Santoro, D., additional, Zappulla, Z., additional, Alibrandi, A., additional, Tomasello Andulajevic, M., additional, Licari, M., additional, Baldari, S., additional, Buemi, M., additional, Cernaro, V., additional, Campenni, A., additional, Pallet, N., additional, Chauvet, S., additional, Levi, C., additional, Meas-Yedid, V., additional, Beaune, P., additional, Thevet, E., additional, Karras, A., additional, Santos, S., additional, Malheiro, J., additional, Campos, A., additional, Pedroso, S., additional, Santos, J., additional, Cabrita, A., additional, Mayor, M. M., additional, Ayala, R., additional, Ramos, C., additional, Franco, S., additional, Guillen, R., additional, Kim, J. S., additional, Yang, J. W., additional, Han, B. G., additional, Choi, S. O., additional, Tudor, M.-N., additional, Navajas Martinez, M. F., additional, Vaduva, C., additional, Maria, D. T., additional, Mota, E., additional, Clari, R., additional, Mongilardi, E., additional, Vigotti, F. N., additional, Consiglio, V., additional, Scognamiglio, S., additional, Nazha, M., additional, Roggero, S., additional, Piga, A., additional, Piccoli, G., additional, Mukhopadhyay, P., additional, Patar, K., additional, Chaterjee, N., additional, and Ganguly, K., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results